Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRAPPA: PTCY vs ATG for graft-versus-host disease prophylaxis in unrelated donor PBSC transplantation
2023-510441-24-00Phase 3Completed
- Sponsor
- DKMS
- Start
- Sep 2024
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cyclophosphamide and antithymocyte globulin rabbit in graft-versus-host disease (GVHD) (2 arms), sponsored by DKMS. Primary endpoints: Overall survival from randomization and Graft-versus-host disease-free and relapse-free survival. Started Sep 2024; status: completed.
02
Drugs
cyclophosphamideantithymocyte globulin rabbit
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on 2023-510441-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510441-24-00.